Find information on thousands of medical conditions and prescription drugs.

Zoladex

Goserelin is an injectable gonadotropin releasing hormone agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen) and is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

Goserelin is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling LHRHa in the world. It is currently available in more than one hundred markets.

Read more at Wikipedia.org


[List your site here Free!]


Zoladex Before Ablation Leads to Better Outcomes
From OB/GYN News, 4/1/01 by Sharon Worcester

ORLANDO, FLA. -- Pretreatment with goserelin acetate improves long-term outcomes in patients undergoing endometrial ablation for dysfunctional uterine bleeding, a recent study found.

The 358 premenopausal patients in the study were treated with either placebo or 3.6 mg of depot goserelin acetate (Zoladex). Two injections were given 28 days apart. The procedure was performed about 6 weeks after the first injection, Dr. George A. Vilos reported at the annual meeting of the American Association of Gynecologic Laparoscopists.

Amenorrhea rates at a 6-month follow up were 40% in the goserelin acetate group and 26% in the placebo group. At 1 year, the rates were 35% and 22%; at 3 years, they dropped to 21% in the goserelin acetate group and 14% in the placebo group.

"There was a reduction in the amenorrhea rate in both groups, but it appears Zoladex is still holding. It fares a little better [than placebo]," said Dr. Vilos of the University of Western Ontario, London.

Furthermore, the use of goserelin acetate appeared to make surgery easier and quicker by thinning the endometrium. Ultrasound evaluations performed just before endometrial ablation demonstrated a marked decrease in endometrial thickness in the goserelin acetate group, and surgeons scored the procedures in the treatment group as much easier than in the placebo group. Patients in the goserelin acetate group also absorbed less fluid.

As for surgical interventions, hysterectomies occurred in 21% of the goserelin acetate group and 15% of the placebo group. The mean time that hysterectomy patients were able to put off the procedure was 664 days in the goserelin acetate group, compared with 571 days in the placebo group.

Repeat endometrial ablation was performed in 5.6% of the goserelin acetate group and 2.1% of the placebo group. Pain and bleeding were the most common causes for surgical intervention.

COPYRIGHT 2001 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Zoladex
Home Contact Resources Exchange Links ebay